Published in J Ind Microbiol Biotechnol on October 05, 2015
Natural product discovery: past, present, and future. J Ind Microbiol Biotechnol (2016) 1.02
Identification of a novel NAMPT inhibitor by CRISPR/Cas9 chemogenomic profiling in mammalian cells. Sci Rep (2017) 0.75
Prenylated Polyphenols from Clusiaceae and Calophyllaceae with Immunomodulatory Activity on Endothelial Cells. PLoS One (2016) 0.75
Elucidation of the glycosylation steps during biosynthesis of antitumor macrolides PM100117 and PM100118 and engineering for novel derivatives. Microb Cell Fact (2016) 0.75
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature (2009) 19.56
Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov (2006) 15.21
How were new medicines discovered? Nat Rev Drug Discov (2011) 7.00
Cas9 as a versatile tool for engineering biology. Nat Methods (2013) 6.87
Spiroindolones, a potent compound class for the treatment of malaria. Science (2010) 5.94
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov (2010) 5.55
Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat Genet (1999) 5.06
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell (2008) 2.49
Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. Cell Host Microbe (2012) 2.05
Spiroindolone KAE609 for falciparum and vivax malaria. N Engl J Med (2014) 1.99
Ribosomally synthesized thiopeptide antibiotics targeting elongation factor Tu. J Am Chem Soc (2009) 1.92
Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J Med Chem (2010) 1.84
mTOR inhibition improves immune function in the elderly. Sci Transl Med (2014) 1.78
Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe (2013) 1.58
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol (2012) 1.46
Natural products reveal cancer cell dependence on oxysterol-binding proteins. Nat Chem Biol (2011) 1.31
The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease. Angew Chem Int Ed Engl (2011) 1.29
Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis. J Antimicrob Chemother (2008) 1.28
Discovery of LFF571: an investigational agent for Clostridium difficile infection. J Med Chem (2012) 1.26
Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. J Hepatol (2012) 1.22
Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. Br J Pharmacol (2012) 1.19
Clinical status of anti-cancer agents derived from marine sources. Anticancer Agents Med Chem (2008) 1.17
Bugs, drugs and chemical genomics. Nat Chem Biol (2011) 1.15
(-)-Englerin A is a potent and selective activator of TRPC4 and TRPC5 calcium channels. Angew Chem Int Ed Engl (2015) 1.14
The discovery of first-in-class drugs: origins and evolution. Nat Rev Drug Discov (2014) 1.14
Functional analysis of Hsp70 inhibitors. PLoS One (2013) 1.13
Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex. ACS Chem Biol (2013) 1.12
Mass spectrometry-based proteomics in preclinical drug discovery. Chem Biol (2012) 1.04
High-resolution chemical dissection of a model eukaryote reveals targets, pathways and gene functions. Microbiol Res (2013) 1.03
The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother (2014) 1.02
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. Antimicrob Agents Chemother (2014) 1.01
Discovery and characterization of the tuberculosis drug lead ecumicin. Org Lett (2014) 1.01
Argyrins, immunosuppressive cyclic peptides from myxobacteria. I. Production, isolation, physico-chemical and biological properties. J Antibiot (Tokyo) (2002) 1.00
Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571. Antimicrob Agents Chemother (2012) 0.98
Bacterial caseinolytic proteases as novel targets for antibacterial treatment. Int J Med Microbiol (2013) 0.92
An allosteric Sec61 inhibitor traps nascent transmembrane helices at the lateral gate. Elife (2014) 0.92
Everolimus. Recent Results Cancer Res (2014) 0.91
Antibiotic optimization and chemical structure stabilization of thiomuracin A. J Med Chem (2012) 0.90
Everolimus in heart transplantation: an update. J Transplant (2013) 0.90
Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation. PLoS One (2015) 0.89
Lifespan-extending caloric restriction or mTOR inhibition impair adaptive immunity of old mice by distinct mechanisms. Aging Cell (2014) 0.89
Structural basis of malaria parasite lysyl-tRNA synthetase inhibition by cladosporin. J Struct Funct Genomics (2014) 0.88
Recent developments in antibacterial drug discovery: microbe-derived natural products--from collection to the clinic. Expert Opin Investig Drugs (2006) 0.87
Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrob Agents Chemother (2014) 0.86
Targeting the eIF4A RNA helicase as an anti-neoplastic approach. Biochim Biophys Acta (2014) 0.86
Structure of Prolyl-tRNA Synthetase-Halofuginone Complex Provides Basis for Development of Drugs against Malaria and Toxoplasmosis. Structure (2015) 0.85
Nannocystin A: an Elongation Factor 1 Inhibitor from Myxobacteria with Differential Anti-Cancer Properties. Angew Chem Int Ed Engl (2015) 0.85
Antibiotics A21459 A and B, new inhibitors of bacterial protein synthesis. II. Structure elucidation. J Antibiot (Tokyo) (1996) 0.84
Identification of elongation factor G as the conserved cellular target of argyrin B. PLoS One (2012) 0.83
Decatransin, a new natural product inhibiting protein translocation at the Sec61/SecYEG translocon. J Cell Sci (2015) 0.83
Imatinib mesylate. Recent Results Cancer Res (2014) 0.81
The novolactone natural product disrupts the allosteric regulation of Hsp70. Chem Biol (2014) 0.81
Euphohelioscopin A is a PKC activator capable of inducing macrophage differentiation. Chem Biol (2012) 0.79
Gift from Nature: Cyclomarin A Kills Mycobacteria and Malaria Parasites by Distinct Modes of Action. Chembiochem (2015) 0.78
Everolimus: preventing organ rejection in adult kidney transplant recipients. Expert Opin Pharmacother (2012) 0.78
Discovery, Structure Elucidation, and Biological Characterization of Nannocystin A, a Macrocyclic Myxobacterial Metabolite with Potent Antiproliferative Properties. Angew Chem Int Ed Engl (2015) 0.78
Integrated compound profiling screens identify the mitochondrial electron transport chain as the molecular target of the natural products manassantin, sesquicillin, and arctigenin. ACS Chem Biol (2012) 0.78
Everolimus in liver transplantation. Curr Opin Organ Transplant (2014) 0.76
Trial watch: Next-generation antimalarial from phenotypic screen shows clinical promise. Nat Rev Drug Discov (2014) 0.76
Evolution of targeted therapies in cancer: opportunities and challenges in the clinic. Future Oncol (2015) 0.75